Clinical Trial Search

Primary: Change From Baseline in the Rasch-transformed Score of the FACE-Q Satisfaction With Facial Appearance Scale. — 46.6 units on a scale — p=<0.0001

Primary: Number of Participants Reporting Product Tolerability Based on Evaluator Global Assessment Scores — 47; 44; 0; 0 Participants

Primary: Number of Participants With Evaluator (Dermatologist) Global Assessment (EGA) Score for Well Tolerance of Product 14 Days Post-Procedure — 36; 38 Participants — p=0.3334

Primary: Cosmetic Appearance Preference — 8; 9; 4; 5 participants

Primary: Change From Baseline in Rasch-transformed Score of FACE-Q Satisfaction With Facial Appearance Overall Scale to End of Study — 40.9; 37.8; 21.5; 32.9 score on a scale…

Primary: Overall Preference — 49.1; 24.6 Percentage of participants

Primary: C-GAIS by the PI or Designee — 1.22; 2.13; 1.75; 2.75 units on a scale

Primary: Distance Monocular logMAR Visual Acuity — -0.159; -0.157 logMAR

Primary: Evaluate Overall Facial Improvement Assessed Live by the Investigator and Subjects Using the Global Aesthetic Improvement Scale (GAIS) at 12 Weeks Compared to Baseline…

Primary: Patient Satisfaction With Validated FACE-Q Aesthetics Survey — 28.0; 24.0; 36.0; 36.0 score on a scale

Primary: Change From Baseline in Overall Photodamage Score — 5.6; -0.8 score on a scale — p=<0.001

Primary: Combined Skin Irritation (Dermal Response) and Superficial Irritation (Other Effects) Scores at Induction Phase at Day 2 — 0; 0 Score on scale

Primary: Frequency of Combined Dermatologist Score — 1; 1; 51; 55 Participants

Primary: Distance Monocular Visual Acuity (logMAR) — -0.016; -0.001; -0.171; -0.151 logMAR

Primary: Blistering Time (Full Blister) — 63; 54; 65; 62 Minutes

Primary: Number of Participants With a Unit Change of Greater Than (>) 1 in Signs and Symptoms of Cutaneous Irritation Total Scores From Baseline to 21 Days of Product Use — 3; 0…

Primary: Change From Baseline in Ra (a dermaTOP Parameter), of Test Product Treated Versus (vs.) Untreated Side at Day 29 — -1.90; -0.12 Micro meter (µm) — p=0.0638

Primary: Change From Baseline in Corneometer Values at 8 Hours on Day 1 — 6.14; 2.63; 3.60 Arbitrary Corneometer unit — p=0.0128

Primary: Change From Baseline in Transepidermal Water Loss (TEWL) Measurements on Day 29, Test Product Treated Versus (vs.) Untreated Sites on the Forearm — -0.59; 0.79 gram…

Primary: Percentage of Participants With Potential Sensitisation Reactions as Assessed by Dermatologist on Day 40 — 2; 1; 1; 0 Number of participants

Primary: FACE-Q Satisfaction With Facial Appearance Overall Scale — 42.35; 59.42 score on a scale

Primary: Hypertrophic Scarring (HTS) as Assessed by Score on the Manchester Scar Scale (MSS) Rated by Blinded Plastic Surgeons — 7; 9 score on a scale

Primary: Change in Wrinkle Appearance — 19.0; 23.2 percentage of reduced fine wrinkles

Primary: Distance Binocular Visual Acuity (logMAR) — -0.15; -0.18; 0.00; -0.04 logMAR

Primary: Logarithm of Percentage of Baseline Ulcer Size — 3.6043; 3.5030 Mean of log (percentage of baseline area — p=0.652

Primary: Graded Change in Dermatochalasis — .2679 units on a scale

Primary: Plaque Index of Test Mouth Rinse Versus Sterile Water After Day 4 of Treatment Administration — 3.03; 3.23 Score on a scale — p=0.0915

Primary: Responders Rate Using the Global Aesthetic Improvement Scale (GAIS) at Maximum Frown (Glabellar Lines) — 100 percentage of participants

Primary: Mean Subject Self Reported Quality of Life Scale — 3.45 units on a scale

Primary: The First Visit Onset of Efficacy as Measured by Physician Assessment — 2.2 Number of Days